Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.

chinamoneynetwork.com October 16, 2019

Vivo Capital Leads $50M Series B Round In Chinese Cro Firm Dmed Biopharmaceutical - China Money Network

dMed Biopharmaceutical Co., Ltd., a Chinese full service Clinical Contract Research Organization (CRO), announces on Wednesday that it has completed nearly US$50 million in a series B financing round.
Read by 75% of LPs

chinamoneynetwork.com October 16, 2019

Vivo Capital Leads $50M Series B Round In Chinese Cro Firm Dmed Biopharmaceutical - China Money Network

dMed Biopharmaceutical Co., Ltd., a Chinese full service Clinical Contract Research Organization (CRO), announces on Wednesday that it has completed nearly US$50 million in a series B financing round. The round is led by healthcare-focused investment firm Vivo Capital, with participation from Chinese venture capital firm Legend Capital, Chinese Qiming Venture Partners and Shanghai-based biomedical [...] Vivo Capital Leads $50M Series B Round In Chinese CRO Firm dMed Biopharmaceutical comes originally from China Money Network. All Rights Reserved.
Read by 70% of LPs

chinamoneynetwork.com October 10, 2019

Dashenlin Pharmaceutical-backed Genetic Testing Start-up Genebox Raises $14M In Series A Round From Centurium Capital - China Money Network

Chinese health management platform Genebox, also known as Jiyinbao has secured around RMB100 million (US$14 million) in a series A funding round led by Chinese private equity investment firm Centurium Capital, according to Chinese media outlet 36Kr on Wednesday. Founded in 2018, Genebox helps customers to sequence their genome and send them a report on [...] DaShenLin Pharmaceutical-backed Genetic Testing Start-Up Genebox Raises $14 M In Series A Round From Centurium Capital comes originally from China Money Network. All Rights Reserved.
Read by 64% of LPs

businesswire.com September 05, 2019

Continuus Pharmaceuticals Raises $5M In Series B Round, Led By Mark Bamforth Who Will Join The Board Of Directors

WOBURN, Mass.--(BUSINESS WIRE)--On August 26, 2019, CONTINUUS Pharmaceuticals Inc., a leading technology company working on continuous manufacturing of pharmaceuticals, completed a $5 M Series B financing. This round was led by Mark Bamforth, President & CEO at Arranta Bio, with participation by IMA Industria Macchine Automatiche and other investors from previous rounds. Bamforth will also join the Board of Directors of CONTINUUS, bringing decades of experience in commercial pharmaceutical.
Read by 36% of LPs

chinamoneynetwork.com July 31, 2019

Hongtai Capital Leads $14M Series A+ Round In Chinese Pharmaceutical Firm - China Money Network

Chinese pharmaceutical firm CGeneTech has raised over RMB100 million (US$14.52 million) in a series A+ round of financing led by Hongtai Capital, a venture capital firm co-established by the founder of Chinese education giant New Oriental Education. ABC International, an investment banking business of Agricultural Bank of China Limited (ABC), also participated in this round, [...] Hongtai Capital Leads $14M Series A+ Round In Chinese Pharmaceutical Firm comes originally from China Money Network. All Rights Reserved.
Read by 48% of LPs

pehub.com July 18, 2019

Vc-backed Mirum Pharmaceuticals Debuts Ipo

Foster City, California-based Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has raised $75 million for its IPO after pricing its 5 million shares at [...]
Read by 35% of LPs

businesswire.com July 15, 2019

Recursion Pharmaceuticals Secures $121M In Series C Financing

SALT LAKE CITY--(BUSINESS WIRE)--#biotech--Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.
Read by 48% of LPs

prnewswire.com July 11, 2019

Demetrix Secures $50M In Series A Funding To Provide Cannabinoids To Pharmaceutical, Supplement, And Consumer Product Companies

EMERYVILLE, Calif., July 11, 2019 /PRNewswire/ -- Today, Demetrix Inc., a biotechnology company focused on the production of cannabinoids, announced that it has secured $50 million in Series A funding. The round was led by Tuatara Capital with participation from existing investor Horizons ...
Read by 35% of LPs

vcaonline.com May 29, 2019

Ayala Pharmaceuticals Raises $30M In Series B Financing

REHOVOT, Israel & WILMINGTON, Del., May 28, 2019-- Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced the successful completion of a $30 million Series B financing. The investment was led by Novartis with participation from SBI JI Innovation Fund and all existing investors, including Israel Biotech Fund, aMoon and Harel Insurance & Finance Group. The new capital will fuel Ayala's plans to advance the clinical development of lead product candidate AL101, a pan-Notch inhibitor that is currently being evaluated for adenoid cystic carcinoma (ACC).
Read by 71% of LPs

vcnewsdaily.com May 20, 2019

Reneo Pharmaceuticals Raises $50M In Series A

SAN DIEGO, CA, Clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing.
Read by 63% of LPs